Unknown

Dataset Information

0

Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.


ABSTRACT: Recent evidence suggest that a ?-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. Here, we demonstrate that intravenous injection of K3-SPG, but not CpG alone, is accumulated in the tumor microenvironment and triggered immunogenic cell death (ICD) of tumor cells by local induction of type-I interferon (IFN) as well as IL-12. Resultant innate immune activation as well as subsequent tumor-specific CD8 T cell responses were contributed the tumor growth suppression. This anti-tumor effect of K3-SPG monotherapy was also confirmed by using various tumor models including pancreatic cancer peritoneal dissemination model. Taken together, nano-particulate TLR9 agonist injected intravenously can scout out tumor microenvironment to provoke local innate immune activation and release dead tumor cells into circulation that may induce broader and protective tumor antigen-specific CD8 T cells.

SUBMITTER: Kitahata Y 

PROVIDER: S-EPMC5226476 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.

Kitahata Yuji Y   Kanuma Tomohiro T   Hayashi Masayuki M   Kobayashi Nobuyoshi N   Ozasa Koji K   Kusakabe Takato T   Temizoz Burcu B   Kuroda Etsushi E   Yamaue Hiroki H   Coban Cevayir C   Yamamoto Takuya T   Kobiyama Kouji K   Aoshi Taiki T   Ishii Ken J KJ  

Oncotarget 20160801 31


Recent evidence suggest that a β-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. Here, we demonstrate that intravenous injection of K3-SPG, but not CpG alone, is accumulated in the tumor microenvironment and triggered i  ...[more]

Similar Datasets

| S-EPMC6844329 | biostudies-literature
| 2063196 | ecrin-mdr-crc
| S-EPMC3917779 | biostudies-literature
| S-EPMC9750861 | biostudies-literature
| S-EPMC6425432 | biostudies-other
| S-EPMC9753984 | biostudies-literature
| S-EPMC3364192 | biostudies-literature
| S-EPMC10996274 | biostudies-literature
| S-EPMC4517169 | biostudies-literature
| S-EPMC10514162 | biostudies-literature